Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.47 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.45 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.42 |
| ▸ | GRIN2D known ✓ | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B known ✓ | O60391 | 2/20 | 0.42 |
| ▸ | GRIN1 known ✓ | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B known ✓ | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C known ✓ | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 2/20 | 0.42 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29622030 | 1.00 | MAPT (0.52) | MAPTHTTNPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL31130340 | 1.00 | MAPT (0.52) | MAPTHTTNPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL11291134 | 0.97 | MAPT (0.50) | MAPTHTTNPC1RAB9AALDH1A1 | |
| SCHEMBL787 | 0.97 | — | — | |
| SCHEMBL29518635 | 0.97 | — | — | |
| Dimethylamine SCHEMBL7262452 | 0.92 | MAPT (0.50) | MAPTHTTNPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL6015036 | 0.92 | MAPT (0.50) | MAPTHTTNPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL5044406 | 0.81 | TDP1 (0.44) | MAPTHTTNPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL30951582 | 0.80 | MAPT (0.50) | MAPTHTTNPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL28769409 | 0.80 | MAPT (0.50) | MAPTHTTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 622 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119219504-B | Method for synthesizing triarylmethane molecular skeleton by aromatic aldehyde and hydrazine hydrochloride substance | 山东金科力电源科技有限公司 | 2025-03-14 | — | — | CN | claimed |
| CN-119219504-A | Method for synthesizing triarylmethane molecular skeleton by aromatic aldehyde and hydrazine hydrochloride substance | 山东金科力电源科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4326702-A1 | METHODS FOR SYNTHESIS OF AN ADVANTAGEOUS N-HETEROCYCLIC CARBENE CATALYST | XF Technologies Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| US-20240059701-A1 | Methods for Synthesis of an Advantageous N-Heterocyclic Carbene Catalyst | XF BIOSOLUTIONS, LLC | 2024-02-22 | — | — | US | claimed |
| CN-117529466-A | Method for synthesizing favorable N-heterocyclic carbene catalyst | 埃克斯福科技公司 | 2024-02-06 | — | — | CN | claimed |
| CN-114560814-B | Synthesis method of substituted 2, 3-naphthyridine ketone compound | 天津理工大学 | 2023-10-20 | — | — | CN | claimed |
| CN-114452912-B | Preparation method of polysubstituted nitrogen-containing heterocyclic methylamine compound | 上海罕道医药科技有限公司 | 2023-09-12 | — | — | CN | claimed |
| WO-2022225825-A1 | METHODS FOR SYNTHESIS OF AN ADVANTAGEOUS N-HETEROCYCLIC CARBENE CATALYST | XF TECHNOLOGIES INC. (US) | 2022-10-27 | — | — | WO | claimed |
| CN-114560814-A | Synthesis method of substituted 2, 3-phthalazinone compound | 天津理工大学 | 2022-05-31 | — | — | CN | claimed |
| CN-114452912-A | Preparation method of polysubstituted nitrogen-containing heterocyclic methylamine compound | 上海罕道医药科技有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-122079894-A | Preparation method of N-aryl pyrazole compound | — | 2026-05-26 | — | — | CN | disclosed |
| US-12577456-B2 | Light-emitting element, light-emitting device, electronic device, lighting device, and novel organic compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| EP-4707276-A2 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4499611-B1 | MALT1 MODULATORS AND USES THEREOF | RAREFIED BIOSCIENCES INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | RAREFIED BIOSCIENCES, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-4062864-A | ANALGESIC, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-4046753-A | ANTHELMINTICS, HYPOTENSIVE | MERCK & CO., INC. (US) | 1977-09-06 | — | — | US | disclosed |
| US-4017540-A | INSECTICIDES, MITICIDES | THE UPJOHN COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-3959309-A | ANALGESICS, PSYCHOTROPIC, ANTIHISTAMINE | STERLING DRUG INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3932661-A | Anthelmintic methods employing benzoyl chloride phenylhydrazones | THE UPJOHN COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | MALT1, SQSTM1, PPP1R10 | GAA 215/4885ACHE 4597/4885SIGMAR1 3892/4885 |
| US-12577456-B2 | Light-emitting element, light-emitting device, electronic device, lighting device, and novel organic compound | SUN2, LEF1, CTNND1 | GAA 4725/4885ACHE 1298/4885SIGMAR1 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.